Sanofi US News

- Two-Dose Series Given at Regularly Scheduled Pediatric Visits Demonstrates Strong Immune Responses -

Growth Platforms(2) reached over 70% of sales

- QIV is the next evolution of influenza vaccine designed to help protect against influenza B, a significant cause of influenza illness and associated complications across all ages, and especially children -

– CDC analysis of 10 influenza seasons indicates use of a four-strain vaccine could have prevented 2.7 million influenza cases, 21 thousand influenza-related hospitalizations and almost 1,400 influenza-related deaths(1) –

Establishment of joint project teams will leverage strengths of academic and industry cross-organizational expertise in all stages of translational research

U.S. Senator Robert P. Casey, Jr. and Former First Lady Of Pennsylvania Ellen Casey Co-Chair Event

- Goal is to select novel clinical development candidates to help stop the global pandemic -

- Everyone 6 months of age and older recommended for yearly vaccination

Recent survey findings indicate majority of adults fear spreading the flu to family and friends, yet only a third of adults 18 through 64 years of age get a flu shot